X-Therma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

X-Therma is developing a breakthrough biopreservation platform that emulates natural antifreeze mechanisms to enable longer, safer storage of biological materials. Its lead programs include XT-Thrive for cell therapy cryopreservation and XT-ViVo/TimeSeal for organ preservation, the latter having received FDA Breakthrough Device Designation in 2022. The company addresses significant unmet needs in organ transplantation, cell manufacturing, and IVF, where current standards using DMSO are toxic and limiting. By removing time and toxicity as barriers, X-Therma aims to unlock the full potential of regenerative medicines and organ transplants.

Organ TransplantationRegenerative Medicine

Technology Platform

Bio-inspired, chemically defined antifreeze molecule platform that inhibits ice crystal formation for non-toxic, extended biopreservation of cells, tissues, and organs at ultra-low and high subzero temperatures.

Opportunities

The massive unmet need in organ transplantation (80% discard rate) and the rapid growth of the cell & gene therapy market, which requires scalable, non-toxic biopreservation, represent billion-dollar opportunities.

FDA Breakthrough Device Designation provides a accelerated pathway to market for its organ preservation system.

Risk Factors

Key risks include the technical challenge of translating subzero preservation to human organs, regulatory hurdles for a novel device/biologic combination, and market adoption against entrenched standards like DMSO and static cold storage.

Competition in the biopreservation space is also increasing.

Competitive Landscape

X-Therma competes with traditional DMSO-based media suppliers and static cold storage in organ transport. In organ preservation, it faces competition from normothermic machine perfusion systems (e.g., TransMedics, OrganOx). In cryopreservation media, it competes with other DMSO-free media developers. Its bio-inspired, subzero approach is a key differentiator.

More companies in Regenerative Medicine →More companies in Austria →